B. Riley Securities Reiterates Buy Rating on Whitehawk Therapeutics
B. Riley Securities maintains its buy rating on Whitehawk Therapeutics with a $10 price target, a 140.38% upside from the current price.
Key Points
- B. Riley Securities reiterated its buy rating on Whitehawk Therapeutics, Inc. (WHWK) with a target price of $10.
- B. Riley Securities's $10 price target implies 140.38% upside from Whitehawk Therapeutics, Inc.'s ($WHWK) current $4.16 share price.
- Shares of Whitehawk Therapeutics traded near $4.39 on Thursday with a market cap of approximately $220.6 million.
- Recent insider activity included multiple insider purchases on June 12, 2026, while analysts maintain a buy recommendation.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
B. Riley Securities has reiterated its buy rating for Whitehawk Therapeutics, Inc. (NasdaqCM: WHWK), setting a target price of $10. This reaffirmation came on June 25, 2026, as shares traded near $4.39.
B. Riley Securities vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Whitehawk Therapeutics, Inc. Stock Down 10.0%
Shares of NasdaqCM:WHWK traded around $4.39 on Thursday. Whitehawk Therapeutics, a biotechnology company, has a market cap of approximately $220.6 million. The company is not currently profitable, so it has no meaningful P/E ratio. The stock's 52-week range is between $1.57 and $5.50, with a 50-day moving average of $4.20 and a 200-day moving average of $3.02. It maintains a strong current ratio of 11.356, indicating solid liquidity.
$WHWK price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Whitehawk Therapeutics has not reported revenue growth recently. Its earnings per share (EPS) is negative at -$2.49, and it holds a net margin of 0.0%. The return on equity (ROE) is -68.5%. Investors are looking forward to the next earnings report expected on August 6, 2026.
Insider Buying and Selling at Whitehawk Therapeutics, Inc.
On June 12, 2026, several insiders, including Caley Castelein, Neil Desai, Emma Reeve, Richard Maroun, Baiteng Zhao, and Behzad Aghazadeh, each acquired 38,040 shares of Whitehawk Therapeutics. These purchases were not part of any pre-planned trading program.
Analysts Set New Price Targets
On June 25, 2026, B. Riley Securities reiterated its buy rating on Whitehawk Therapeutics with a $10 price target. Previously, Citizens initiated coverage with a buy rating and an $8 target on April 16, 2026. Jones Trading also began coverage with a buy rating and a $7 target on December 22, 2025. The overall analyst consensus remains a buy, with a mean target price of $6.5 based on four opinions.
About Whitehawk Therapeutics
Whitehawk Therapeutics, Inc. is a clinical-stage biotechnology company based in Morristown, New Jersey. It focuses on developing oncology therapeutics, particularly in the area of antibody drug conjugates (ADCs) for cancer treatment. Led by CEO Dr. David J. Lennon, the company employs 29 people and was formerly known as Aadi Bioscience, Inc. before changing its name in August 2021.
Bottom Line
Whitehawk Therapeutics, Inc. continues to attract attention with its promising cancer treatment technologies. B. Riley Securities' reiteration of a buy rating suggests confidence in the company's future prospects. However, as a clinical-stage biotech firm, its financials reflect the typical challenges of pre-revenue companies. Investors should note that analyst ratings are based on past data and may not reflect current market conditions.
Get Whitehawk Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $WHWK, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.